Adial Pharmaceuticals Inc(ADIL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 5:35 PM ET (Korea 10/1 06:35)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -16.54 | Insider Own | 9.2% | Shs Outstand | 2.6M | Perf Week | -0.74% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 76.54% | Insider Trans | 19.83% | Shs Float | 2.4M | Perf Month | -30.26% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.17 | Inst Own | 19.41% | Short Float | 8.82% | Perf Quarter | 42.7% |
| Income | -0.06B | P/S | - | EPS this Y | 78.21% | Inst Trans | 8.44% | Short Ratio | 3.61 | Perf Half Y | 124.02% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 61.9% | ROA | -322.1% | Short Interest | 0.21M | Perf YTD | -27.09% |
| Book/sh | -14.61 | P/C | 0.37 | EPS past 3/5Y | 88.55% 53.46% | ROE | -265.94% | 52W High | -62.7% ($10.75) | Perf Year | -54.63% |
| Cash/sh | 10.93 | P/FCF | - | Sales past 3/5Y | - | ROIC | -241.16% | 52W Low | 206.11% ($1.31) | Perf 3Y | -94.23% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.78% | Gross Margin | - | Volatility(W/M) | 11.88% 11.43% | Perf 5Y | -99.85% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.52 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.63 | EPS Q/Q | -144.05% | Profit Margin | - | RSI (14) | 38.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.63 | Sales Q/Q | - | SMA20 | -21.67% ($5.12) | Beta | 1.5 | Target Price | $8.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/17 | SMA50 | -15.05% ($4.72) | Rel Volume | 0.61 | Prev Close | $4.15 |
| Employees | 6 | LT Debt/Eq | - | EPS/Sales Surpr. | -989.59% - | SMA200 | 15.66% ($3.47) | Avg Volume(3M) | 0.06M | Price | $4.01 |
| IPO | 2018/7/27 | Option/Short | No/Yes | Trades | 840 | Volume | 35,280 | Change | -3.37% |
🧬 A biotech focused on addiction treatment. AD04 is a therapeutic for alcohol use disorder. Phase 3 trials are set to begin in the second half of 2025, with the FDA approval pathway already in progress.
Over the past 1 year, roughly in the middle
63% below its 1-year high.
Traded less than usual That is 61% of its average volume.
ADIL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +78.2% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #506 of 592 in the industry
Based on market cap of $11M.
ADIL#506 Adial Pharmaceuticals Inc $11M PER - 
MTVA#507 MetaVia Inc $10M PER - 
TOVX#508 Theriva Biologics Inc $10M PER - 
MBRX#509 Moleculin Biotech Inc $10M PER - 
XTLB#510 X.T.L. Biopharmaceuticals Ltd ADR $10M PER - 
FAQ
What kind of company is ADIL?
ADIL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ADIL?
The market cap of ADIL is approximately $11M, ranking 5,466 within its sector.
What is the 52-week high and low for ADIL?
ADIL has recorded a 52-week high of $10.75 and a low of $1.31.
